Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL964134 | 0.80 | POLB (0.53) | POLBKDM4EHPGDMAPK1ATM | |
| SCHEMBL2293796 | 0.80 | POLB (0.54) | POLBKDM4EHPGDMAPK1ATM | |
| SCHEMBL2080828 | 0.78 | POLB (0.51) | POLBKDM4EHPGDMAPK1ATM | |
| SCHEMBL19121927 | 0.78 | POLB (0.51) | POLBKDM4EHPGDMAPK1ATM | |
| SCHEMBL2079170 | 0.74 | GAA (0.50) | POLBKDM4EMAPK1ATMMEN1 | |
| SCHEMBL851142 | 0.74 | POLB (0.47) | POLBKDM4EHPGDMAPK1ATM | |
| SCHEMBL2618578 | 0.73 | KDM4E (0.43) | POLBKDM4EHPGDMAPK1ATM | |
| SCHEMBL3411375 | 0.69 | NAMPT (0.37) | — | |
| SCHEMBL1746338 | 0.69 | — | — | |
| SCHEMBL898966 | 0.69 | CA12 (0.62) | POLBMAPK1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183380-B2 | 2-aminoquinolines | HOFFMANN-LA ROCHE INC. (US) | 2012-05-22 | — | — | US | claimed |
| EP-2262789-A1 | 2-AMINOQUINOLINES | F. Hoffmann-La Roche AG (CH) | 2010-12-22 | — | — | EP | claimed |
| WO-2009109477-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-11 | — | — | WO | claimed |
| US-20090227570-A1 | 2-AMINOQUINOLINES | HOFFMANN-LA ROCHE, INC. | 2009-09-10 | — | — | US | claimed |
| US-9233947-B2 | Sulfamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2016-01-12 | — | — | US | disclosed |
| US-20140243329-A1 | SULFAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-28 | — | — | US | disclosed |
| US-8748478-B2 | Sulfamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2014-06-10 | — | — | US | disclosed |
| EP-2379521-B1 | SULFAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-22 | — | — | EP | disclosed |
| US-20130237547-A1 | SULFAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-09-12 | — | — | US | disclosed |
| US-8436041-B2 | Sulfamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-07 | — | — | US | disclosed |
| US-8183380-B2 | 2-aminoquinolines | HOFFMANN-LA ROCHE INC. (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2262789-A1 | 2-AMINOQUINOLINES | F. Hoffmann-La Roche AG (CH) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010080397-A1 | SULFAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-15 | — | — | WO | disclosed |
| US-20100160337-A1 | SULFAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2010-06-24 | — | — | US | disclosed |
| WO-2009109477-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227570-A1 | 2-AMINOQUINOLINES | HOFFMANN-LA ROCHE, INC. | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237547-A1 | SULFAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | POLB 4606/4885KDM4E 2906/4885HPGD 3449/4885 |
| US-20100160337-A1 | SULFAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | POLB 4606/4885KDM4E 2906/4885HPGD 3449/4885 |
| US-20140243329-A1 | SULFAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | POLB 4606/4885KDM4E 2906/4885HPGD 3449/4885 |
| US-20090227570-A1 | 2-AMINOQUINOLINES | HTR5A, HTR2C, HTR2A | POLB 4179/4885KDM4E 1399/4885HPGD 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.